Results 81 to 90 of about 14,935 (222)

BCR::ABL1‐Induced Enhancer Reprogramming Uncovers Hypersensitivity of Ph+B‐ALL Cells to Enhancer‐Targeting Drugs

Advanced Science, Volume 13, Issue 25, 4 May 2026.
Ng et al. show that the BCR::ABL1 kinase that drives the lymphoid leukemia Ph+B‐ALL modulates enhancer function by coopting signaling‐inducible transcription factors such as MYC, STAT5, and ETV5. BCR::ABL1 thereby promotes the transcriptional program driving and defining this leukemia and renders Ph+B‐ALL cells hypersensitive to enhancer‐inhibiting ...
Han Leng Ng, Trudy Lee Glaser, Jintao Zhu, Mark E. Robinson, Kadriye N. Cosgun, Valeriya Malysheva, Ozgen Deniz, Nicholas T. Crump, Kaiyue Helian, Andrew J. Innes, Richard Burt, Li Sun, George John, Haibin Zhou, Atsunori Kaneshige, Longchuan Bai, Shaomeng Wang, Mikhail Spivakov, Markus Müschen, Niklas Feldhahn   +19 more
wiley   +1 more source

Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study [PDF]

, 2016
There is an increasing interest for monitoring circulating myeloid-derived suppressor cells (MDSCs) in cancer patients, but there are also divergences in their phenotypic definition.
Brandau, Sven, Britten, Cedrik M, Bronte, Vincenzo, Damuzzo, Vera, Gouttefangeas, C\ue9cile, Mandruzzato, Susanna, Maurer, Dominik, Ottensmeier, Christian, van der Burg, Sjoerd H, Walter, Steffen, Welters, Marij J. P   +10 more
core   +2 more sources

Fixed‐Duration Subcutaneous Mosunetuzumab in Relapsed/Refractory Follicular Lymphoma: Pivotal Phase 2 Primary Analysis

American Journal of Hematology, Volume 101, Issue 5, Page 986-997, May 2026.
ABSTRACT Mosunetuzumab is approved as an intravenous (IV) formulation for relapsed/refractory (R/R) follicular lymphoma (FL) after ≥ 2 prior therapies. A subcutaneous (SC) formulation, aiming to improve patient safety and convenience, has been developed.
Nancy L. Bartlett, Laurie H. Sehn, Sarit Assouline, Pratyush Giri, John Kuruvilla, Stephen J. Schuster, Sung‐Soo Yoon, Keith Fay, Georg Hess, Martin Dreyling, Norma C. Gutierrez, Eva Cybulski, Fidelis Sabalvaro, Elicia Penuel, Vanda Teodoro, Samuel Tracy, Denison Kuruvilla, Joseph Chen, Volker Wiebking, Michael C. Wei, L. Elizabeth Budde   +20 more
wiley   +1 more source

Impact of Preanalytical Sample Preparation on the Recovery Rate of Cryopreserved Allogeneic Hematopoietic Stem Cells

European Journal of Haematology, Volume 116, Issue 5, Page 604-614, May 2026.
ABSTRACT Introduction Cryopreservation of peripheral‐blood‐derived hematopoietic stem and progenitor cells (PBSCs) has been used for decades, primarily for autologous transplantation. Now, in the era of new cellular therapies, the cryopreservation of allogeneic PBSCs may also become relevant.
Philipp Blüm, Christina Glas, Karen Bieback, Sabine Kayser, Harald Klüter, Patrick Wuchter   +5 more
wiley   +1 more source

A study on beneficial impact of the use of medium-molecular-weight hydroxyethyl starch in granulocyte apheresis using continuous-flow cell separator Spectra Optia: A retrospective single-center study at a tertiary care oncology center

Asian Journal of Transfusion Science
INTRODUCTION: Granulocyte transfusion is one of the best therapeutic modalities in prolonged neutropenic patients with severe bacterial/fungal infections.
Amardeep Pathak, Devasis Panda, Narender Tejwani, Anurag Mehta   +3 more
doaj   +1 more source

Competitive Activation of a Methyl C−H Bond of Dimethylformamide at an Iridium Center [PDF]

, 2009
During the synthesis of [AsPh_4][Ir(CO)_2I_3Me] by refluxing IrCl_3·3H_2O in DMF (DMF = dimethylformamide) in the presence of aqueous HCl, followed by sequential treatment with [AsPh_4]Cl, NaI, and methyl iodide and finally recrystallization from ...
Bercaw, John E., Day, Michael W., Henling, Lawrence M., Labinger, Jay A., Scott, Valerie J.   +4 more
core   +1 more source

Frontline Therapy in Diffuse Large B‐Cell Lymphoma: Evolving Standards, Biological Insights, and Future Directions

European Journal of Haematology, Volume 116, Issue 5, Page 522-534, May 2026.
ABSTRACT Diffuse large B‐cell lymphoma (DLBCL) remains the most common aggressive lymphoma, representing a biologically heterogeneous disease with diverse clinical behaviors. For more than two decades, R‐CHOP has been the cornerstone of frontline treatment, curing approximately two‐thirds of patients.
Mamdouh Skafi, Santino Caserta, Ernesto Vigna, Antonella Bruzzese, Nicola Amodio, Eugenio Lucia, Virginia Olivito, Caterina Labanca, Francesco Mendicino, Maria Eugenia Alvaro, Fortunato Morabito, Enrica Antonia Martino, Massimo Gentile   +12 more
wiley   +1 more source

Cancer Vaccines: A Ray of Hope [PDF]

, 2014
In lieu of an abstract, here are the article\u27s first two paragraphs: Recent cancer statistics review by Surveillance, Epidemiology, and End Results (SEER) Program by National Cancer Institute (NCI) shows that cancer is the second most leading cause of
Chablani, Lipika
core   +1 more source

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. [PDF]

, 2019
BackgroundThe large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant ...
Armstrong, Andrew J, Chang, Nancy N, Concepcion, Raoul S, Cooperberg, Matthew R, Harmon, Matt, Higano, Celestia S, Kantoff, Philip W, Kassabian, Vahan, McLeod, David G, Nordquist, Luke T, Penson, David F, Pieczonka, Christopher M, Quinn, David I, Sartor, A Oliver, Scholz, Mark C, Shore, Neal D, Tang, Hong, Tutrone, Ronald F, Tyler, Robert C, Vacirca, Jeffrey, Vogelzang, Nicholas J   +20 more
core   +2 more sources

Manufacturing and clinical applications of non‐CAR‐T immune effector cells

Transfusion, EarlyView.
Thane Kubik, Theodros Mamo, David H. McKenna   +2 more
wiley   +1 more source